ABSTRACT
There is ample empirical evidence that cultivation of mindfulness in dedicated target populations has positive health effects, specifically in the context of stress management and mental disorders. Research into the effectiveness of mindfulness-based interventions (MBI) in age-related conditions and disorders is still in its infancy. This paper describes, in brief, the scientific background of MBI and its potential to contribute to successful ageing and the care for and wellbeing of older people. Special focus is dedicated to the contribution of optimal cognitive abilities to this success and to what extent MBI may support cognitive reserve.
Subject(s)
Aging/psychology , Cognition/physiology , Mindfulness , Aged , Female , Health Services for the Aged , Humans , Male , Stress, Psychological/prevention & controlABSTRACT
OBJECTIVE: To examine the associations of fatty acid and fish intake with cognitive function. METHODS: Data are from a cross-sectional population-based study among 1,613 subjects ranging from 45 to 70 years old. From 1995 until 2000, an extensive cognitive battery was administered and compound scores were constructed for memory, psychomotor speed, cognitive flexibility (i.e., higher order information processing), and overall cognition. A self-administered food-frequency questionnaire was used to assess habitual food consumption. The risk of impaired cognitive function (lowest 10% of the compound score) according to the energy adjusted intake of fatty acids was assessed with logistic regression, adjusting for age, sex, education, smoking, alcohol consumption, and energy intake. RESULTS: Marine omega-3 polyunsaturated fatty acids (PUFA) (eicosapentaenoic acid and docosahexaenoic acid) were inversely related to the risk of impaired overall cognitive function and speed (per SD increase: OR = 0.81, 95% CI 0.66 to 1.00 and OR = 0.72, 95% CI 0.57 to 0.90). Results for fatty fish consumption were similarly inverse. Higher dietary cholesterol intake was significantly associated with an increased risk of impaired memory and flexibility (per SD increase: OR = 1.27, 95% CI 1.02 to 1.57 and OR = 1.26, 95% CI 1.01 to 1.57). Per SD increase in saturated fat intake, the risk of impaired memory, speed, and flexibility was also increased, although not significantly. CONCLUSIONS: Fatty fish and marine omega-3 PUFA consumption was associated with a reduced risk and intake of cholesterol and saturated fat with an increased risk of impaired cognitive function in this middle-aged population.
Subject(s)
Cognition/drug effects , Dietary Fats/pharmacology , Fatty Acids, Omega-3/pharmacology , Fatty Acids/pharmacology , Fish Oils/pharmacology , Seafood , Animals , Cholesterol/adverse effects , Cholesterol/pharmacology , Cognition Disorders/epidemiology , Cognition Disorders/etiology , Cohort Studies , Cross-Sectional Studies , Eicosapentaenoic Acid/pharmacology , Fatty Acids, Unsaturated/pharmacology , Female , Humans , Life Style , Male , Middle AgedABSTRACT
Phosphatidylserine (PS) is a phospholipid which has been claimed to enhance neuronal membrane function, and can be derived from several sources. Earlier studies used brain cortex derived PS, of which the human tolerability of 300mg daily in 130 patients has been shown. The human tolerability of PS derived from soybean has not been reported, although it is widely sold as a nutritional supplement which may improve cognitive function in the elderly. We report the results of a study of the safety of two dosages of soy-phosphatidylserine (S-PS) in elderly. Subjects were 120 elderly of both sexes who fulfilled the more stringent criteria for age-associated memory impairment; some also fulfilled the criteria for age-associated cognitive decline. Subjects were allocated at random to one of the three treatment groups: placebo, 300 or 600 mg S-PS daily. Standard biochemical and hematological safety parameters, blood pressure, heart rate and adverse events were assessed at baseline, after 6 and 12 weeks of treatment. No significant differences were found in any of the outcome variables between the treatment groups after Bonferonni-Holme correction. In conclusion, soy derived PS is a safe nutritional supplement for older persons if taken up to a dosage of 200 mg three times daily.
Subject(s)
Dietary Supplements , Glycine max , Memory Disorders/prevention & control , Phosphatidylserines/therapeutic use , Aged , Alanine Transaminase/blood , Blood Pressure/drug effects , Dose-Response Relationship, Drug , Female , Heart Rate/drug effects , Humans , Leukocyte Count , Male , Multivariate Analysis , Phosphatidylserines/administration & dosage , Phosphatidylserines/adverse effects , Placebos , Platelet Count , Safety , Treatment OutcomeABSTRACT
Phosphatidylserine (PS) is a phospholipid widely sold as a nutritional supplement. PS has been claimed to enhance neuronal membrane function and hence cognitive function, especially in the elderly. We report the results of a clinical trial of soybean-derived PS (S-PS) in aging subjects with memory complaints. Subjects were 120 elderly (> 57 years) of both sexes who fulfilled the more stringent criteria for age-associated memory impairment (AAMI); some also fulfilled the criteria for age-associated cognitive decline. Subjects were allocated at random to one of the three treatment groups: placebo, 300mg S-PS daily, or 600mg S-PS daily. Assessments were carried out at baseline, after 6 and 12 weeks of treatment, and after a wash-out period of 3 weeks. Tests of learning and memory, choice reaction time, planning and attentional functions were administered at each assessment. Delayed recall and recognition of a previously learned word list comprised the primary outcome measures. No significant differences were found in any of the outcome variables between the treatment groups. There were also no significant interactions between treatment and 'severity of memory complaints'. In conclusion, a daily supplement of S-PS does not affect memory or other cognitive functions in older individuals with memory complaints.